Lingke Medical Secures Tens of Millions in Pre-A Funding to Advance Therapeutic Hypothermia for Neuroprotection

Recently, focusing on intelligent temperature control management,Lingke Medical Technology (Hangzhou) Co., Ltd.(abbreviated as“Lingke Medical”) announced the completion of a tens-of-millions-of-yuan Pre-A financing round, which was led byDelian Capital Neuroscience FundExclusive Investment. The successful completion of this financing round not only injects strong momentum into the company’s subsequent R&D, product commercialization, and market expansion, but also underscores the capital market’s high recognition of the intelligent temperature-controlled therapy sector and Lingke Medical’s core competitiveness.

Ischemic stroke is currently a major disease with high incidence, mortality, and disability rates worldwide. Statistics show that there are over 2 million new stroke cases annually in China, with ischemic stroke accounting for 70%–80%. The onset of this condition is abrupt, and cerebral blood supply obstruction leads to irreversible neuronal damage. Even after vascular recanalization therapy, many patients still suffer from severe sequelae, imposing a heavy burden on families and society. Mild therapeutic hypothermia for neuroprotection is a clinically proven effective neuroprotective strategy. Maintaining body temperature between 32°C and 35°C can mitigate ischemia-reperfusion injury. Recommended by multiple guidelines for early-stage management, it helps reduce infarct volume and improve prognosis. With advancements in temperature control and monitoring technologies, the safety and operability of mild hypothermia therapy continue to improve, offering new hope for patients with ischemic stroke and holding promise as a key adjunctive measure for improving outcomes.

Lingke Medical is a medical technology company specializing in intelligent human body temperature management, established in 2022. Its core focus lies in the research, development, and industrialization of intelligent, precise temperature control therapies. The company provides a precision temperature control treatment platform for critical care areas such as stroke, traumatic brain injury, myocardial infarction, cardiac arrest, and organ transplantation, creating a full-chain solution covering “R&D, production, and application.” Clinical evidence for its self-developed mild hypothermia neuroprotection system is robust, effectively reducing disability and mortality rates after major surgeries, including those for neurological conditions. Furthermore, through its proprietary temperature control systems, Lingke Medical achieves superior clinical performance compared to imported alternatives, offering comprehensive solutions for clinical temperature regulation.

In terms of business layout, Lingke Medical is guided by clinical needs and has established a comprehensive product portfolio. This portfolio features two core product lines—intravascular temperature control systems (including consumables) and non-invasive surface temperature control systems (including consumables)—while also positioning future products such as localized and portable temperature control systems. These solutions cover multiple clinical scenarios, including neurosurgery, cardiology, intensive care units (ICU), and emergency departments. Clinical data for the intravascular temperature control system demonstrate that the company’s solution significantly reduces the incidence of complications in stroke patients. The product is safe and effective, contributing to the effective resolution of cerebral edema, a significant reduction in cerebral infarction volume, and a substantial improvement in favorable prognosis rates, thereby earning widespread recognition from clinicians.

As the first innovative enterprise in China’s field of precise endovascular temperature-controlled therapy, Lingke Medical’s core competitiveness is primarily reflected in two areas: technological barriers and team advantages. The company boasts a robust core team, with founding members possessing extensive experience in R&D, regulatory registration, and operations within the medical device industry, characterized by solid technical expertise and seamless collaboration. Furthermore, the company engages in deep cooperation with top-tier physician teams, participating throughout the clinical design and validation processes. This “medical-engineering integration” model accelerates product iteration. In terms of core technology, the company has developed a high-precision temperature control system with an accuracy of ±0.3°C, achieved through millivolt-level hardware dual-loop temperature sampling, software coordination, and peristaltic pump speed control, thereby meeting the requirements of international Targeted Temperature Management (TTM) guidelines. Additionally, the system integrates an AI-based self-sensing module that automatically generates personalized temperature control curves based on individual patient parameters. Currently, these technologies are protected by dozens of granted patents, establishing a solid technological barrier.

Going forward, the company will also conduct refined research and development and iterative upgrades of its precise temperature control technology based on clinical needs, leveraging machine learning and artificial intelligence optimization to meet diverse clinical demands and generate greater social benefits.

In the future, Lingke Medical will strictly focus on its core business, significantly increase R&D investment in core technologies, and continuously optimize the performance of intelligent temperature control devices and consumables. The company will drive technological innovation and breakthroughs by tackling key technical challenges such as precise low-temperature control and ultra-fast response, while strengthening its patent portfolio to lay the foundation for subsequent product iterations. Meanwhile, it will accelerate clinical validation and commercialization, advance regulatory submissions for intravascular and non-invasive surface temperature control systems, establish a standardized production system, and achieve large-scale manufacturing and sales to meet bulk clinical demands.

Founder of Lingke MedicalHe stated, “The successful completion of this Pre-A financing round would not have been possible without the trust and support of Delian Capital, nor without the relentless efforts of our team. Since its inception, Lingke Medical has remained true to its original mission of ‘empowering critical care through technological innovation’ and ‘building a company with warmth,’ focusing on technological breakthroughs and product commercialization in the field of intelligent temperature-controlled therapy. Leveraging our core technological advantages—such as intelligent precise temperature control and AI-driven self-sensing adaptation—along with a comprehensive product portfolio, our products have demonstrated favorable clinical outcomes in pilot programs at multiple Grade A tertiary hospitals. They effectively address the pain points of temperature management in critical care, breaking the monopoly held by foreign brands. Looking ahead, the company will seize this financing opportunity to deepen its focus on core business areas, continuously enhance product competitiveness and clinical value, promote the widespread adoption and upgrading of intelligent temperature-controlled therapy technologies, and contribute to improving China’s capabilities in the prevention and control of cardiovascular and cerebrovascular diseases as well as the treatment of critical and severe conditions, thereby bringing greater benefits to more patients.”

Relevant Person in Charge at Delian CapitalIt stated: “Achieving precise target temperature management is an essential intervention for neurocritical care, cardiac arrest, and perioperative brain protection, providing an effective means to reduce mortality and disability rates in critical illnesses. Lingke Medical has strategically positioned itself in this sector by leveraging three core advantages: technological leadership, robust clinical evidence, and controllable costs. Its products have gained recognition from leading hospitals in China. The team boasts over twenty years of experience in the research, development, and regulatory registration of multinational medical devices. In the future, the company is poised to rapidly grow into a leading enterprise in the fields of precise temperature management and neuroprotection in China.”

The Delian Bojian Brain Science Fund, initiated by Delian Capital and backed by investors including the Shanghai Future Industry Fund, Sanbo Brain Hospital, Shibei Hi-Tech, and Minhang Financial Investment, focuses on strategic investments in frontier fields such as brain-computer interfaces, neuromodulation, and the diagnosis and treatment of neurological and psychiatric disorders. It aims to build a “technology–investment–clinical” ecosystem for the brain science industry, providing portfolio companies with comprehensive empowerment through financial, clinical, and industrial resources.